| Therapeutic | Sovipostobart |
| Target | CTLA4/CD152 |
| Heavy Chain | QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYTMHWVRQAPGKGLEWVTFISYDGNNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAIYYCARTGWLGPFDYWGQGTLVTVSS |
| Light Chain | EIVLTQSPGTLSLSPGERATLSCRASQSVGSSYLAWYQQKPGQAPRLLIYGAFSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK |
| 100% seqID Fv Structure | 5tru [Fvs: HL, hl], 5xj3 [Fvs: AB, DE, GH, JK], 6jc2 [Fvs: HL], 6rp8 [Fvs: HL, hl], 7elx [Fvs: HL, hl] |
| 99% seqID Fv Structure | None |
| 95-98% seqID Fv Structure | None |
| 100% seqID Structure | 5tru [Fvs: HL, hl] |
| 100% seqID Structure | 5xj3 [Fvs: AB, DE, GH, JK] |
| 100% seqID Structure | 6jc2 [Fvs: HL] |
| 100% seqID Structure | 6rp8 [Fvs: HL, hl] |
| 100% seqID Structure | 7elx [Fvs: HL, hl] |
Follow these links to our prediction tools:
| Format | Whole mAb |
| Isotype | G1 |
| Highest Clinical Trial (Aug '24) | Phase-II |
| Estimated Status (Aug '24) | Active |
| Recorded Developmental Technology | |
| INN Year Proposed | 2023 |
| INN Year Recommended | 2023 |
| Companies Involved | CytomX Therapeutics, Bristol-Myers Squibb |
| Conditions Approved | na |
| Conditions Active | Malignant melanoma, Solid tumours |
| Conditions Discontinued | na |
| Notes | Danvilostomig Fv1;Ipilimumab; Sovipostobart; and Tazlestobart all have the same sequence. Cleavable prodomain. |
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]
Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]
